BJP RCPsych Publications
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by STEPHENSON, C. M. E.
Right arrow Articles by PILOWSKY, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by STEPHENSON, C. M. E.
Right arrow Articles by PILOWSKY, L. S.
The British Journal of Psychiatry (2000) 177: 408-415
© 2000 The Royal College of Psychiatrists

Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo

[123I]-epidepride single photon emission tomography(SPET) study

C. M. E. STEPHENSON, MRCPsych, V. BIGLIANI, BS, H. M. JONES, MRCPsych, R. W. KERWIN, FRCPsych and L. S. PILOWSKY, MRCPsych

Institute of Psychiatry, London

R. S. MULLIGAN, Msc, D. VISVIKIS, PhD and P. J. ELL, FRCP

Institute of Nuclear Medicine, UCL Medical School, Middlesex Hospital, London

P. D. ACTON, PhD

Department of Radiology, University of Pennsylvania

Correspondence: C. M. E. Stephenson, c/o L. S. Pilowsky, Department of Psychological Medicine, Section of Neurochemical Imaging, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK

Declaration of interest C.M.E.S. and H.M.J. were supported by research grants from Astra Zeneca, V.B. by a research grant from Eli Lilly and R.S.M. by a UK Medical Research Council (MRC) Senior Clinical Research Fellowship Award. L.S.P. is a UK MRC Senior Clinical Research Fellow.

Background Selective action at limbic cortical dopamine D2-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects.

Aims To test the hypothesis that quetiapine has ‘limbic selective’ D2/D3 receptor occupancy in vivo.

Method The high-affinity D2/D3 ligand [123I]-epidepride and single photon emission tomography were used to estimate D2/D3 specific binding and an index of relative percentage D2/D3 occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared.

Results Mean (s.d.) relative percentage D2/D3 receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day).

Quetiapine treatment resulted in limbic selective D2/D3 blockade similar to clozapine and significantly higher than typical antipsychotics.

Conclusions Preliminary data suggest that limbic selective D2/D3 receptor blockade is important for atypical drug action.




This article has been cited by other articles:


Home page
Schizophr BullHome page
J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky
Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature
Schizophr Bull, February 26, 2008; (2008) sbn009v1.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
J. M. Stone, P. D. Morrison, and L. S. Pilowsky
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
J Psychopharmacol, June 1, 2007; 21(4): 440 - 452.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
M. J. Dunkley and M. A. Reveley
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma
J Psychopharmacol, January 1, 2005; 19(1): 97 - 101.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
R. A. Bressan, H. M. Jones, and L. S. Pilowsky
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity
J Psychopharmacol, March 1, 2004; 18(1): 124 - 127.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
R. A. Bressan, K. Erlandsson, H. M. Jones, R. Mulligan, R. J. Flanagan, P. J. Ell, and L. S. Pilowsky
Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
Am J Psychiatry, August 1, 2003; 160(8): 1413 - 1420.
[Abstract] [Full Text] [PDF]


Home page
Br. J. PsychiatryHome page
H. M. JONES and L. S. PILOWSKY
Dopamine and antipsychotic drug action revisited
The British Journal of Psychiatry, October 1, 2002; 181(4): 271 - 275.
[Full Text] [PDF]


Home page
Br. J. PsychiatryHome page
X. XIBERAS, J. L. MARTINOT, L. MALLET, E. ARTIGES, C. LOC'H, B. MAZIERE, and M. L. PAILLERE-MARTINOT
Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia
The British Journal of Psychiatry, December 1, 2001; 179(6): 503 - 508.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 2000 The Royal College of Psychiatrists.